Windlas Biotech
894.55
+16.20(+1.84%)
Market Cap₹1,888.06 Cr
PE Ratio27.89
IndustryHealthcare
Company Performance:
1D+1.84%
1M+23.00%
6M-5.97%
1Y-13.88%
5Y+119.71%
View Company Insightsright
More news about Windlas Biotech
13Mar 26
Windlas Biotech Allots 28,990 Equity Shares Under Employee Stock Option Plans
Windlas Biotech Limited allotted 28,990 equity shares of Rs.5/- each on March 13, 2026, under two employee stock option schemes. The allocation included 4,115 shares from the 2021 plan and 24,875 shares from the 2023 scheme. The company has notified both BSE and NSE exchanges about this corporate action for regulatory compliance.
 no imag found
10Feb 26
Windlas Biotech Receives Show Cause Notice for Temporary Suspension of Codeine Cough Syrup Manufacturing
Windlas Biotech Limited received a show cause notice from Uttarakhand's Food Safety & Drug Administration on February 9, 2026, leading to temporary suspension of codeine-containing cough syrup manufacturing. The affected product line contributed Rs. 55.21 crore to revenue in the current financial year till February 9, 2026. The company is preparing its response within stipulated timelines while other manufacturing operations continue normally.
 no imag found
05Feb 26
Windlas Biotech Re-appoints Three Directors for Five-Year Terms
Windlas Biotech Limited re-appointed three key directors for five-year terms following a February 5, 2026 Board meeting. Mr. Ashok Kumar Windlass was re-appointed as Whole-time Director from May 3, 2026 to May 2, 2031, while Independent Directors Mr. Vivek Dhariwal and Mr. Gaurav Gulati received second five-year terms from May 6, 2026 to May 5, 2031. All appointments are subject to shareholder approval and ensure leadership continuity with experienced professionals.
 no imag found
05Feb 26
Windlas Biotech Board Approves Dissolution of Non-Operating US Subsidiary
Windlas Biotech Limited's Board of Directors approved the dissolution of Windlas Inc. USA, a non-operating wholly owned subsidiary, on February 5, 2026. The subsidiary reported zero turnover for FY 2024-25 and negative net worth of USD -1923.10, contributing 0% to the parent company's operations. The company will file dissolution application under Delaware laws with no consideration expected from the process.
 no imag found
05Feb 26
Windlas Biotech Q3 Results: Revenue Growth Offset by Declining Margins and EBITDA
Windlas Biotech's Q3 results showed strong revenue growth of 18% reaching ₹2.30 billion, but profitability metrics declined with net profit down 3.2% to ₹150 million, EBITDA falling marginally to ₹244 million, and EBITDA margin compressing significantly to 10.47% from 12.62% year-on-year, indicating operational efficiency challenges.
 no imag found
28Jan 26
Windlas Biotech Schedules Board Meeting on February 5, 2026 for Q3FY26 Financial Results
Windlas Biotech Limited has scheduled a board meeting for February 5, 2026, to consider and approve unaudited standalone and consolidated financial results for Q3FY26, covering the quarter and nine months ended December 31, 2025. The meeting complies with SEBI LODR Regulation 29 requirements. The company's trading window remains closed from January 1, 2026, and will reopen 48 hours after financial results declaration, ensuring compliance with insider trading regulations.
 no imag found
12Nov 25
Windlas Biotech Reports 19% Revenue Growth in Q2 FY26, Unveils ESOP 2025 Scheme
Windlas Biotech achieved 19% year-on-year revenue growth for both Q2 and H1 FY26, with revenue from operations at INR 222.00 crores for Q2 and INR 432.00 crores for H1. EPS for H1 FY26 increased by 21% to INR 16.91. The company saw growth across all business verticals, with Generic Formulations CDMO growing 18%, Trade Generics & Institutional up 25%, and Exports rising 23% in H1 FY26. Windlas Biotech also implemented an ESOP 2025 scheme covering about 100 employees. The company's injectable facility gained new customer approvals, and the Plant-6 expansion is on track for commissioning within FY26.
 no imag found
06Nov 25
Windlas Biotech Targets Export Growth and Margin Expansion Through Strategic Initiatives
Windlas Biotech Limited, a leading pharmaceutical CDMO, is implementing strategic initiatives for stronger export growth and margin expansion. The company is leveraging FDA-compliant facilities for U.S. market access, expanding CDMO partnerships, and diversifying its product portfolio into nutrition, injectables, and contract manufacturing. Margin improvement strategies include focusing on high-value products and integrating with global supply chains. Financial results show positive growth with revenue up 19.40% YoY to ₹4325.00 crore in H1 FY26. The company reported strong performance across all business verticals and continues to invest in manufacturing infrastructure.
 no imag found
06Nov 25
Windlas Biotech Reports 13.7% Rise in Q2 Net Profit, Declares Rs 5.80 Dividend
Windlas Biotech Limited announced robust Q2 FY26 results, with revenue from operations increasing 18.9% YoY to Rs 2,223.98 crore. EBITDA grew 23.9% to Rs 286.00 crore, and net profit rose 13.7% to Rs 178.00 crore. The company achieved its highest-ever half-yearly revenue of Rs 4,324.88 crore in H1 FY26, up 19.4% YoY. The Board approved a final dividend of Rs 5.80 per share for FY 2024-25. All business verticals showed growth, with Generic Formulations CDMO growing 17.7%, Trade Generics & Institutional up 24.2%, and Exports expanding 13.0% YoY in Q2 FY26. The company continues to invest in manufacturing infrastructure and capacity enhancement.
 no imag found
24Aug 25
Windlas Biotech Refines Employee Stock Option Plan with Clarified Grant Limits
Windlas Biotech Limited has made key amendments to its Windlas Plan 2025 employee stock option plan. The changes include retaining the overall limit of 3,15,000 units per eligible employee and introducing a new annual grant limit of 2,09,590 units per employee. Grants equal to or exceeding 1% of the company's issued capital will require additional compliance measures. These amendments aim to align with SEBI disclosure requirements and do not alter the maximum limits approved by shareholders. No units have been issued under the plan yet, pending regulatory approval.
 no imag found
22May 25
Windlas Biotech Reports Q4 Revenue Growth, Recommends Dividend
Windlas Biotech's Q4 results show mixed performance. Revenue increased 18.71% to ₹2.03 billion, and EBITDA rose to ₹255.50 million. However, net profit slightly decreased by 4.18% to ₹162.80 million year-over-year. The company maintained a 12.60% EBITDA margin and recommended a dividend of ₹5.80 per equity share.
 no imag found
Windlas Biotech
894.55
+16.20
(+1.84%)
1 Year Returns:-13.88%
Industry Peers
Sun Pharmaceutical
1,680.10
(+0.62%)
Divis Laboratories
6,378.50
(+1.48%)
Torrent Pharmaceuticals
4,147.20
(+1.53%)
Dr Reddys Laboratories
1,331.00
(+9.37%)
Lupin
2,341.40
(+1.45%)
Cipla
1,305.90
(+5.63%)
Zydus Life Science
946.35
(+1.77%)
Mankind Pharma
2,292.90
(+2.59%)
Aurobindo Pharma
1,435.40
(+1.00%)
Alkem Laboratories
5,520.50
(-1.89%)